nodes	percent_of_prediction	percent_of_DWPC	metapath
Pindolol—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0875	0.137	CbGbCtD
Pindolol—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0822	0.129	CbGbCtD
Pindolol—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0822	0.129	CbGbCtD
Pindolol—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0744	0.116	CbGbCtD
Pindolol—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0744	0.116	CbGbCtD
Pindolol—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0642	0.1	CbGbCtD
Pindolol—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0623	0.0974	CbGbCtD
Pindolol—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0564	0.0881	CbGbCtD
Pindolol—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0564	0.0881	CbGbCtD
Pindolol—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000491	0.00147	CcSEcCtD
Pindolol—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00049	0.00146	CcSEcCtD
Pindolol—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00049	0.00146	CcSEcCtD
Pindolol—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00049	0.00146	CcSEcCtD
Pindolol—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.000489	0.00146	CcSEcCtD
Pindolol—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000489	0.00146	CcSEcCtD
Pindolol—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000488	0.00146	CcSEcCtD
Pindolol—Tension—Lamivudine—acquired immunodeficiency syndrome	0.000487	0.00146	CcSEcCtD
Pindolol—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000487	0.00145	CcSEcCtD
Pindolol—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000487	0.00145	CcSEcCtD
Pindolol—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000486	0.00145	CcSEcCtD
Pindolol—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000486	0.00145	CcSEcCtD
Pindolol—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000486	0.00145	CcSEcCtD
Pindolol—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000485	0.00145	CcSEcCtD
Pindolol—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000485	0.00145	CcSEcCtD
Pindolol—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.000482	0.00144	CcSEcCtD
Pindolol—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000482	0.00144	CcSEcCtD
Pindolol—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000481	0.00144	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000481	0.00144	CcSEcCtD
Pindolol—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000479	0.00143	CcSEcCtD
Pindolol—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000478	0.00143	CcSEcCtD
Pindolol—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000478	0.00143	CcSEcCtD
Pindolol—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000478	0.00143	CcSEcCtD
Pindolol—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000477	0.00143	CcSEcCtD
Pindolol—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000477	0.00143	CcSEcCtD
Pindolol—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000475	0.00142	CcSEcCtD
Pindolol—Rash—Didanosine—acquired immunodeficiency syndrome	0.000474	0.00142	CcSEcCtD
Pindolol—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000474	0.00142	CcSEcCtD
Pindolol—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000474	0.00142	CcSEcCtD
Pindolol—Headache—Didanosine—acquired immunodeficiency syndrome	0.000471	0.00141	CcSEcCtD
Pindolol—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000471	0.00141	CcSEcCtD
Pindolol—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00047	0.0014	CcSEcCtD
Pindolol—Shock—Delavirdine—acquired immunodeficiency syndrome	0.00047	0.0014	CcSEcCtD
Pindolol—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000469	0.0014	CcSEcCtD
Pindolol—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000469	0.0014	CcSEcCtD
Pindolol—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000468	0.0014	CcSEcCtD
Pindolol—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000468	0.0014	CcSEcCtD
Pindolol—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000467	0.00139	CcSEcCtD
Pindolol—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000466	0.00139	CcSEcCtD
Pindolol—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000465	0.00139	CcSEcCtD
Pindolol—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000465	0.00139	CcSEcCtD
Pindolol—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000464	0.00139	CcSEcCtD
Pindolol—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000464	0.00138	CcSEcCtD
Pindolol—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000463	0.00138	CcSEcCtD
Pindolol—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000462	0.00138	CcSEcCtD
Pindolol—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000462	0.00138	CcSEcCtD
Pindolol—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000461	0.00138	CcSEcCtD
Pindolol—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.00046	0.00138	CcSEcCtD
Pindolol—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.00046	0.00138	CcSEcCtD
Pindolol—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.00046	0.00138	CcSEcCtD
Pindolol—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000459	0.00137	CcSEcCtD
Pindolol—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000458	0.00137	CcSEcCtD
Pindolol—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000456	0.00136	CcSEcCtD
Pindolol—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000455	0.00136	CcSEcCtD
Pindolol—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000455	0.00136	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000455	0.00136	CcSEcCtD
Pindolol—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000452	0.00135	CcSEcCtD
Pindolol—Pain—Indinavir—acquired immunodeficiency syndrome	0.000452	0.00135	CcSEcCtD
Pindolol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000451	0.00135	CcSEcCtD
Pindolol—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00045	0.00135	CcSEcCtD
Pindolol—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000449	0.00134	CcSEcCtD
Pindolol—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000448	0.00134	CcSEcCtD
Pindolol—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000448	0.00134	CcSEcCtD
Pindolol—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000447	0.00134	CcSEcCtD
Pindolol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000447	0.00134	CcSEcCtD
Pindolol—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000446	0.00133	CcSEcCtD
Pindolol—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000446	0.00133	CcSEcCtD
Pindolol—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000445	0.00133	CcSEcCtD
Pindolol—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000445	0.00133	CcSEcCtD
Pindolol—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000445	0.00133	CcSEcCtD
Pindolol—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000444	0.00132	CcSEcCtD
Pindolol—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000443	0.00132	CcSEcCtD
Pindolol—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000443	0.00132	CcSEcCtD
Pindolol—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000443	0.00132	CcSEcCtD
Pindolol—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000442	0.00132	CcSEcCtD
Pindolol—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000441	0.00132	CcSEcCtD
Pindolol—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00044	0.00132	CcSEcCtD
Pindolol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000439	0.00131	CcSEcCtD
Pindolol—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000437	0.0013	CcSEcCtD
Pindolol—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000435	0.0013	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000435	0.0013	CcSEcCtD
Pindolol—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000434	0.0013	CcSEcCtD
Pindolol—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000433	0.00129	CcSEcCtD
Pindolol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000433	0.00129	CcSEcCtD
Pindolol—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000433	0.00129	CcSEcCtD
Pindolol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000432	0.00129	CcSEcCtD
Pindolol—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000432	0.00129	CcSEcCtD
Pindolol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000432	0.00129	CcSEcCtD
Pindolol—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000431	0.00129	CcSEcCtD
Pindolol—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000431	0.00129	CcSEcCtD
Pindolol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00043	0.00128	CcSEcCtD
Pindolol—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.00043	0.00128	CcSEcCtD
Pindolol—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000429	0.00128	CcSEcCtD
Pindolol—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000428	0.00128	CcSEcCtD
Pindolol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000427	0.00127	CcSEcCtD
Pindolol—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000427	0.00127	CcSEcCtD
Pindolol—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000427	0.00127	CcSEcCtD
Pindolol—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000427	0.00127	CcSEcCtD
Pindolol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000426	0.00127	CcSEcCtD
Pindolol—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000426	0.00127	CcSEcCtD
Pindolol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000426	0.00127	CcSEcCtD
Pindolol—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000425	0.00127	CcSEcCtD
Pindolol—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000424	0.00127	CcSEcCtD
Pindolol—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000424	0.00127	CcSEcCtD
Pindolol—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000423	0.00126	CcSEcCtD
Pindolol—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000423	0.00126	CcSEcCtD
Pindolol—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000423	0.00126	CcSEcCtD
Pindolol—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000421	0.00126	CcSEcCtD
Pindolol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.00042	0.00126	CcSEcCtD
Pindolol—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000418	0.00125	CcSEcCtD
Pindolol—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000417	0.00125	CcSEcCtD
Pindolol—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000417	0.00124	CcSEcCtD
Pindolol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000417	0.00124	CcSEcCtD
Pindolol—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000415	0.00124	CcSEcCtD
Pindolol—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000414	0.00124	CcSEcCtD
Pindolol—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000413	0.00123	CcSEcCtD
Pindolol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000413	0.00123	CcSEcCtD
Pindolol—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000412	0.00123	CcSEcCtD
Pindolol—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000412	0.00123	CcSEcCtD
Pindolol—Rash—Stavudine—acquired immunodeficiency syndrome	0.000412	0.00123	CcSEcCtD
Pindolol—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000412	0.00123	CcSEcCtD
Pindolol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000412	0.00123	CcSEcCtD
Pindolol—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000411	0.00123	CcSEcCtD
Pindolol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000411	0.00123	CcSEcCtD
Pindolol—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000411	0.00123	CcSEcCtD
Pindolol—Headache—Stavudine—acquired immunodeficiency syndrome	0.000409	0.00122	CcSEcCtD
Pindolol—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000409	0.00122	CcSEcCtD
Pindolol—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000409	0.00122	CcSEcCtD
Pindolol—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000408	0.00122	CcSEcCtD
Pindolol—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000408	0.00122	CcSEcCtD
Pindolol—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000408	0.00122	CcSEcCtD
Pindolol—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000407	0.00122	CcSEcCtD
Pindolol—Rash—Abacavir—acquired immunodeficiency syndrome	0.000406	0.00121	CcSEcCtD
Pindolol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000405	0.00121	CcSEcCtD
Pindolol—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000405	0.00121	CcSEcCtD
Pindolol—Headache—Abacavir—acquired immunodeficiency syndrome	0.000403	0.0012	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000402	0.0012	CcSEcCtD
Pindolol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000402	0.0012	CcSEcCtD
Pindolol—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000402	0.0012	CcSEcCtD
Pindolol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000399	0.00119	CcSEcCtD
Pindolol—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000399	0.00119	CcSEcCtD
Pindolol—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000398	0.00119	CcSEcCtD
Pindolol—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000397	0.00119	CcSEcCtD
Pindolol—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000396	0.00118	CcSEcCtD
Pindolol—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000394	0.00118	CcSEcCtD
Pindolol—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000394	0.00118	CcSEcCtD
Pindolol—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000393	0.00118	CcSEcCtD
Pindolol—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000392	0.00117	CcSEcCtD
Pindolol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000392	0.00117	CcSEcCtD
Pindolol—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.00039	0.00117	CcSEcCtD
Pindolol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000389	0.00116	CcSEcCtD
Pindolol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000389	0.00116	CcSEcCtD
Pindolol—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000388	0.00116	CcSEcCtD
Pindolol—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000388	0.00116	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000387	0.00116	CcSEcCtD
Pindolol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000384	0.00115	CcSEcCtD
Pindolol—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000382	0.00114	CcSEcCtD
Pindolol—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000382	0.00114	CcSEcCtD
Pindolol—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000381	0.00114	CcSEcCtD
Pindolol—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000381	0.00114	CcSEcCtD
Pindolol—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000379	0.00113	CcSEcCtD
Pindolol—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000379	0.00113	CcSEcCtD
Pindolol—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000379	0.00113	CcSEcCtD
Pindolol—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000378	0.00113	CcSEcCtD
Pindolol—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000377	0.00113	CcSEcCtD
Pindolol—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000377	0.00113	CcSEcCtD
Pindolol—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000377	0.00113	CcSEcCtD
Pindolol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000375	0.00112	CcSEcCtD
Pindolol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000374	0.00112	CcSEcCtD
Pindolol—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000374	0.00112	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000369	0.0011	CcSEcCtD
Pindolol—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000367	0.0011	CcSEcCtD
Pindolol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000367	0.0011	CcSEcCtD
Pindolol—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000366	0.00109	CcSEcCtD
Pindolol—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000364	0.00109	CcSEcCtD
Pindolol—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000364	0.00109	CcSEcCtD
Pindolol—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000363	0.00109	CcSEcCtD
Pindolol—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000363	0.00109	CcSEcCtD
Pindolol—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000361	0.00108	CcSEcCtD
Pindolol—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000361	0.00108	CcSEcCtD
Pindolol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000361	0.00108	CcSEcCtD
Pindolol—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000361	0.00108	CcSEcCtD
Pindolol—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00036	0.00108	CcSEcCtD
Pindolol—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000358	0.00107	CcSEcCtD
Pindolol—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000358	0.00107	CcSEcCtD
Pindolol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000358	0.00107	CcSEcCtD
Pindolol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000357	0.00107	CcSEcCtD
Pindolol—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000356	0.00106	CcSEcCtD
Pindolol—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000353	0.00105	CcSEcCtD
Pindolol—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.00035	0.00105	CcSEcCtD
Pindolol—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00035	0.00105	CcSEcCtD
Pindolol—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000349	0.00104	CcSEcCtD
Pindolol—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000349	0.00104	CcSEcCtD
Pindolol—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000349	0.00104	CcSEcCtD
Pindolol—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000347	0.00104	CcSEcCtD
Pindolol—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000347	0.00104	CcSEcCtD
Pindolol—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000347	0.00104	CcSEcCtD
Pindolol—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000342	0.00102	CcSEcCtD
Pindolol—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000341	0.00102	CcSEcCtD
Pindolol—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000338	0.00101	CcSEcCtD
Pindolol—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000337	0.00101	CcSEcCtD
Pindolol—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000336	0.001	CcSEcCtD
Pindolol—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000336	0.001	CcSEcCtD
Pindolol—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000334	0.000998	CcSEcCtD
Pindolol—Rash—Indinavir—acquired immunodeficiency syndrome	0.000333	0.000995	CcSEcCtD
Pindolol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000333	0.000994	CcSEcCtD
Pindolol—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000331	0.00099	CcSEcCtD
Pindolol—Headache—Indinavir—acquired immunodeficiency syndrome	0.000331	0.000988	CcSEcCtD
Pindolol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00033	0.000985	CcSEcCtD
Pindolol—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000327	0.000976	CcSEcCtD
Pindolol—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00032	0.000957	CcSEcCtD
Pindolol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000317	0.000948	CcSEcCtD
Pindolol—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000317	0.000946	CcSEcCtD
Pindolol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000316	0.000943	CcSEcCtD
Pindolol—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000315	0.00094	CcSEcCtD
Pindolol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000314	0.000939	CcSEcCtD
Pindolol—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000314	0.000937	CcSEcCtD
Pindolol—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000313	0.000934	CcSEcCtD
Pindolol—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000312	0.000933	CcSEcCtD
Pindolol—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000305	0.000911	CcSEcCtD
Pindolol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000304	0.000907	CcSEcCtD
Pindolol—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000302	0.000902	CcSEcCtD
Pindolol—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000301	0.000899	CcSEcCtD
Pindolol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000301	0.000898	CcSEcCtD
Pindolol—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000301	0.000898	CcSEcCtD
Pindolol—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000299	0.000893	CcSEcCtD
Pindolol—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000296	0.000885	CcSEcCtD
Pindolol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000292	0.000872	CcSEcCtD
Pindolol—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000291	0.000869	CcSEcCtD
Pindolol—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000291	0.000868	CcSEcCtD
Pindolol—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000287	0.000857	CcSEcCtD
Pindolol—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000284	0.000847	CcSEcCtD
Pindolol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000281	0.000839	CcSEcCtD
Pindolol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000281	0.000838	CcSEcCtD
Pindolol—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000278	0.000831	CcSEcCtD
Pindolol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000278	0.000831	CcSEcCtD
Pindolol—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000277	0.000828	CcSEcCtD
Pindolol—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000277	0.000826	CcSEcCtD
Pindolol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.00027	0.000807	CcSEcCtD
Pindolol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.000801	CcSEcCtD
Pindolol—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000268	0.0008	CcSEcCtD
Pindolol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000268	0.000799	CcSEcCtD
Pindolol—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000266	0.000795	CcSEcCtD
Pindolol—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000262	0.000783	CcSEcCtD
Pindolol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000258	0.00077	CcSEcCtD
Pindolol—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000256	0.000763	CcSEcCtD
Pindolol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000255	0.000763	CcSEcCtD
Pindolol—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000254	0.000758	CcSEcCtD
Pindolol—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000252	0.000754	CcSEcCtD
Pindolol—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000241	0.000719	CcSEcCtD
Pindolol—HTR1B—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000175	0.00693	CbGpPWpGaD
Pindolol—HTR1B—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000168	0.00665	CbGpPWpGaD
Pindolol—HTR1B—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000168	0.00665	CbGpPWpGaD
Pindolol—HTR1B—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000165	0.00657	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000164	0.0065	CbGpPWpGaD
Pindolol—ADRB3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00016	0.00636	CbGpPWpGaD
Pindolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000157	0.00622	CbGpPWpGaD
Pindolol—HTR1B—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000156	0.00617	CbGpPWpGaD
Pindolol—ADRB1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000154	0.00611	CbGpPWpGaD
Pindolol—ADRB2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000151	0.00597	CbGpPWpGaD
Pindolol—HTR1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000147	0.00584	CbGpPWpGaD
Pindolol—ADRB3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000145	0.00575	CbGpPWpGaD
Pindolol—ADRB3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000143	0.00568	CbGpPWpGaD
Pindolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000142	0.00563	CbGpPWpGaD
Pindolol—ADRB1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000139	0.00552	CbGpPWpGaD
Pindolol—ADRB3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000136	0.0054	CbGpPWpGaD
Pindolol—ADRB3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000136	0.0054	CbGpPWpGaD
Pindolol—ADRB2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000136	0.0054	CbGpPWpGaD
Pindolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000136	0.0054	CbGpPWpGaD
Pindolol—HTR1A—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000136	0.00539	CbGpPWpGaD
Pindolol—HTR1A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000134	0.00533	CbGpPWpGaD
Pindolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000133	0.00529	CbGpPWpGaD
Pindolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000133	0.00529	CbGpPWpGaD
Pindolol—HTR1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000133	0.00528	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000133	0.00528	CbGpPWpGaD
Pindolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000132	0.00523	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00013	0.00517	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00013	0.00515	CbGpPWpGaD
Pindolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000129	0.00512	CbGpPWpGaD
Pindolol—HTR1A—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000128	0.00507	CbGpPWpGaD
Pindolol—HTR1A—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000128	0.00507	CbGpPWpGaD
Pindolol—HTR1B—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000128	0.00506	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000128	0.00506	CbGpPWpGaD
Pindolol—HTR1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000126	0.005	CbGpPWpGaD
Pindolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000125	0.00495	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000125	0.00495	CbGpPWpGaD
Pindolol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000124	0.00492	CbGpPWpGaD
Pindolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000123	0.00486	CbGpPWpGaD
Pindolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000122	0.00485	CbGpPWpGaD
Pindolol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000121	0.00481	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00012	0.00478	CbGpPWpGaD
Pindolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000119	0.00474	CbGpPWpGaD
Pindolol—HTR1B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000119	0.00474	CbGpPWpGaD
Pindolol—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000119	0.0047	CbGpPWpGaD
Pindolol—HTR1B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000115	0.00456	CbGpPWpGaD
Pindolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000113	0.00448	CbGpPWpGaD
Pindolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00011	0.00438	CbGpPWpGaD
Pindolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000108	0.00429	CbGpPWpGaD
Pindolol—HTR1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000108	0.00428	CbGpPWpGaD
Pindolol—HTR1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000107	0.00423	CbGpPWpGaD
Pindolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000106	0.00421	CbGpPWpGaD
Pindolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000106	0.00421	CbGpPWpGaD
Pindolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000104	0.00412	CbGpPWpGaD
Pindolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000104	0.00412	CbGpPWpGaD
Pindolol—ADRB3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000104	0.00411	CbGpPWpGaD
Pindolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000102	0.00403	CbGpPWpGaD
Pindolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000102	0.00403	CbGpPWpGaD
Pindolol—HTR1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000102	0.00403	CbGpPWpGaD
Pindolol—HTR1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000102	0.00403	CbGpPWpGaD
Pindolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000101	0.00402	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.92e-05	0.00394	CbGpPWpGaD
Pindolol—HTR1A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	9.72e-05	0.00386	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.67e-05	0.00384	CbGpPWpGaD
Pindolol—ADRB1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	9.51e-05	0.00377	CbGpPWpGaD
Pindolol—ADRB3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	9.33e-05	0.0037	CbGpPWpGaD
Pindolol—ADRB2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	9.3e-05	0.00369	CbGpPWpGaD
Pindolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	9.14e-05	0.00363	CbGpPWpGaD
Pindolol—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	9.09e-05	0.00361	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.97e-05	0.00356	CbGpPWpGaD
Pindolol—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	8.75e-05	0.00347	CbGpPWpGaD
Pindolol—ADRB1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.6e-05	0.00341	CbGpPWpGaD
Pindolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.49e-05	0.00337	CbGpPWpGaD
Pindolol—ADRB2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.41e-05	0.00334	CbGpPWpGaD
Pindolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.31e-05	0.0033	CbGpPWpGaD
Pindolol—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.22e-05	0.00326	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.22e-05	0.00326	CbGpPWpGaD
Pindolol—ADRB3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.19e-05	0.00325	CbGpPWpGaD
Pindolol—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.12e-05	0.00322	CbGpPWpGaD
Pindolol—ADRB1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	8.08e-05	0.00321	CbGpPWpGaD
Pindolol—ADRB1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	8.08e-05	0.00321	CbGpPWpGaD
Pindolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8.08e-05	0.0032	CbGpPWpGaD
Pindolol—ADRB2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.91e-05	0.00314	CbGpPWpGaD
Pindolol—ADRB2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.91e-05	0.00314	CbGpPWpGaD
Pindolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.9e-05	0.00314	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.9e-05	0.00313	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7.86e-05	0.00312	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.86e-05	0.00312	CbGpPWpGaD
Pindolol—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.73e-05	0.00307	CbGpPWpGaD
Pindolol—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.73e-05	0.00307	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.73e-05	0.00307	CbGpPWpGaD
Pindolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.72e-05	0.00307	CbGpPWpGaD
Pindolol—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.72e-05	0.00306	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.7e-05	0.00306	CbGpPWpGaD
Pindolol—ADRB3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.7e-05	0.00305	CbGpPWpGaD
Pindolol—ADRB3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.7e-05	0.00305	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.55e-05	0.003	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.53e-05	0.00299	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.43e-05	0.00295	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.37e-05	0.00292	CbGpPWpGaD
Pindolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.28e-05	0.00289	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.14e-05	0.00283	CbGpPWpGaD
Pindolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.12e-05	0.00282	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.11e-05	0.00282	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.99e-05	0.00277	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.99e-05	0.00277	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.99e-05	0.00277	CbGpPWpGaD
Pindolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.96e-05	0.00276	CbGpPWpGaD
Pindolol—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.96e-05	0.00276	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.83e-05	0.00271	CbGpPWpGaD
Pindolol—ADRB1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.15e-05	0.00244	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	6.13e-05	0.00243	CbGpPWpGaD
Pindolol—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	6.1e-05	0.00242	CbGpPWpGaD
Pindolol—ADRB2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.02e-05	0.00239	CbGpPWpGaD
Pindolol—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.88e-05	0.00233	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.86e-05	0.00232	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.86e-05	0.00232	CbGpPWpGaD
Pindolol—ADRB3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.86e-05	0.00232	CbGpPWpGaD
Pindolol—ADRB3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.77e-05	0.00229	CbGpPWpGaD
Pindolol—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.74e-05	0.00228	CbGpPWpGaD
Pindolol—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.74e-05	0.00228	CbGpPWpGaD
Pindolol—ADRB1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.54e-05	0.0022	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.54e-05	0.0022	CbGpPWpGaD
Pindolol—ADRB2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.42e-05	0.00215	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.32e-05	0.00211	CbGpPWpGaD
Pindolol—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.3e-05	0.0021	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.3e-05	0.0021	CbGpPWpGaD
Pindolol—ADRB3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.28e-05	0.00209	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.24e-05	0.00208	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.21e-05	0.00207	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.21e-05	0.00207	CbGpPWpGaD
Pindolol—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	5.11e-05	0.00203	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.88e-05	0.00194	CbGpPWpGaD
Pindolol—ADRB1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.86e-05	0.00193	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.86e-05	0.00193	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.79e-05	0.0019	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.77e-05	0.00189	CbGpPWpGaD
Pindolol—ADRB2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.75e-05	0.00189	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.67e-05	0.00185	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.67e-05	0.00185	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.67e-05	0.00185	CbGpPWpGaD
Pindolol—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.65e-05	0.00184	CbGpPWpGaD
Pindolol—ADRB1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.57e-05	0.00181	CbGpPWpGaD
Pindolol—ADRB1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.57e-05	0.00181	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.56e-05	0.00181	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.56e-05	0.00181	CbGpPWpGaD
Pindolol—ADRB2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.47e-05	0.00177	CbGpPWpGaD
Pindolol—ADRB2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.47e-05	0.00177	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.46e-05	0.00177	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.46e-05	0.00177	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.41e-05	0.00175	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.39e-05	0.00174	CbGpPWpGaD
Pindolol—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.37e-05	0.00173	CbGpPWpGaD
Pindolol—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.37e-05	0.00173	CbGpPWpGaD
Pindolol—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.36e-05	0.00173	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.32e-05	0.00171	CbGpPWpGaD
Pindolol—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.3e-05	0.00171	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.22e-05	0.00167	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.22e-05	0.00167	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.15e-05	0.00165	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.15e-05	0.00165	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.13e-05	0.00164	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.13e-05	0.00164	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.13e-05	0.00164	CbGpPWpGaD
Pindolol—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	4.13e-05	0.00164	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.06e-05	0.00161	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.06e-05	0.00161	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.04e-05	0.0016	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	4.02e-05	0.0016	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.97e-05	0.00157	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.97e-05	0.00157	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.96e-05	0.00157	CbGpPWpGaD
Pindolol—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.93e-05	0.00156	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.9e-05	0.00155	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.62e-05	0.00144	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.57e-05	0.00142	CbGpPWpGaD
Pindolol—ADRB1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.48e-05	0.00138	CbGpPWpGaD
Pindolol—ADRB1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.42e-05	0.00136	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.42e-05	0.00136	CbGpPWpGaD
Pindolol—ADRB2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.4e-05	0.00135	CbGpPWpGaD
Pindolol—ADRB2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.35e-05	0.00133	CbGpPWpGaD
Pindolol—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.32e-05	0.00132	CbGpPWpGaD
Pindolol—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.27e-05	0.0013	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.27e-05	0.0013	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.16e-05	0.00125	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.14e-05	0.00125	CbGpPWpGaD
Pindolol—ADRB1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.13e-05	0.00124	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.11e-05	0.00123	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.09e-05	0.00123	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.09e-05	0.00123	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.08e-05	0.00122	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.08e-05	0.00122	CbGpPWpGaD
Pindolol—ADRB2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.06e-05	0.00122	CbGpPWpGaD
Pindolol—ADRB3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.05e-05	0.00121	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.04e-05	0.00121	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.02e-05	0.0012	CbGpPWpGaD
Pindolol—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.99e-05	0.00119	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.97e-05	0.00118	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.88e-05	0.00114	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.84e-05	0.00113	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.83e-05	0.00112	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.82e-05	0.00112	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.78e-05	0.0011	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.77e-05	0.0011	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.76e-05	0.00109	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.72e-05	0.00108	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.61e-05	0.00103	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.55e-05	0.00101	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.49e-05	0.000989	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.45e-05	0.000973	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.45e-05	0.000973	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.4e-05	0.000951	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.4e-05	0.000951	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.34e-05	0.00093	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.34e-05	0.00093	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.34e-05	0.000929	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.31e-05	0.000915	CbGpPWpGaD
Pindolol—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.27e-05	0.000901	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.11e-05	0.000837	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.06e-05	0.000819	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.86e-05	0.00074	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.84e-05	0.000729	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.82e-05	0.000724	CbGpPWpGaD
Pindolol—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.81e-05	0.000718	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.8e-05	0.000713	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.78e-05	0.000708	CbGpPWpGaD
Pindolol—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.77e-05	0.000702	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.76e-05	0.000697	CbGpPWpGaD
Pindolol—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.73e-05	0.000687	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.68e-05	0.000667	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.64e-05	0.000652	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.64e-05	0.000652	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.64e-05	0.000649	CbGpPWpGaD
Pindolol—ADRB3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.63e-05	0.000646	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.61e-05	0.000638	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.61e-05	0.000638	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.57e-05	0.000624	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.22e-05	0.000484	CbGpPWpGaD
Pindolol—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.21e-05	0.000481	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.7e-06	0.000385	CbGpPWpGaD
Pindolol—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.66e-06	0.000383	CbGpPWpGaD
Pindolol—ADRB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.61e-06	0.000381	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.49e-06	0.000377	CbGpPWpGaD
Pindolol—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.45e-06	0.000375	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.28e-06	0.000368	CbGpPWpGaD
Pindolol—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.24e-06	0.000367	CbGpPWpGaD
Pindolol—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.16e-06	0.000284	CbGpPWpGaD
Pindolol—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	7.01e-06	0.000278	CbGpPWpGaD
Pindolol—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.7e-06	0.000226	CbGpPWpGaD
Pindolol—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.58e-06	0.000221	CbGpPWpGaD
Pindolol—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.46e-06	0.000217	CbGpPWpGaD
